(1) By the November interim meeting each year beginning in 2020, the department shall report to the Health and Human Services Interim Committee on: (a) the number of applications and renewal applications filed for medical cannabis cards; (b) the number of qualifying patients and designated caregivers; (c) the nature of the debilitating medical conditions of the qualifying patients; (d) the age and county of residence of cardholders; (e) the number of medical cannabis cards revoked; (f) the number of practitioners providing recommendations for qualifying patients; (g) the number of license applications and renewal license applications received; (h) the number of licenses the department has issued in each county; (i) the number of licenses the department has revoked; (j) the quantity of medical cannabis shipments that the state central patient portal facilitates; (k) the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy; (l) the expenses incurred and revenues generated from the medical cannabis program; and (m) an analysis of product availability in medical cannabis pharmacies.

(a) the number of applications and renewal applications filed for medical cannabis cards;

(b) the number of qualifying patients and designated caregivers;

(c) the nature of the debilitating medical conditions of the qualifying patients;

(d) the age and county of residence of cardholders;

(e) the number of medical cannabis cards revoked;

(f) the number of practitioners providing recommendations for qualifying patients;

(g) the number of license applications and renewal license applications received;

(h) the number of licenses the department has issued in each county;

(i) the number of licenses the department has revoked;

(j) the quantity of medical cannabis shipments that the state central patient portal facilitates;

(k) the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy;

(l) the expenses incurred and revenues generated from the medical cannabis program; and

(m) an analysis of product availability in medical cannabis pharmacies.

(2) The department may not include personally identifying information in the report described in this section.